DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Nourianz is a drug marketed by Kyowa Kirin and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-three patent family members in eighteen countries.
The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the istradefylline profile page.
Nourianz will be eligible for patent challenges on August 27, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2024. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NOURIANZ
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||78|
|Drug Prices:||Drug price information for NOURIANZ|
|What excipients (inactive ingredients) are in NOURIANZ?||NOURIANZ excipients list|
|DailyMed Link:||NOURIANZ at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NOURIANZ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||03063876||Try Before You Buy|
|European Patent Office||2044940||Try Before You Buy|
|South Korea||20150080013||Try Before You Buy|
|South Korea||101098209||Try Before You Buy|
|Brazil||0306919||Try Before You Buy|
|South Korea||20120103740||Try Before You Buy|
|Japan||2009067807||Try Before You Buy|
|>Country||>Patent Number||>Estimated Expiration|